toxylact: a07bc02 kaolin
The first professional lActological database in the word
Kaolin (ATC A07BC02) is a non‑absorbed intestinal adsorbent and demulcent clay used in some antidiarrheal and gut‑protective preparations, with zero gastrointestinal bioavailability and a very low expected risk during breastfeeding.atcddd.fhi+3
ATC A07BC02 overview
ATC code A07BC02 designates kaolin within the subgroup “Other intestinal adsorbents” (A07BC), part of the intestinal adsorbents class A07B among antidiarrheals. In clinical practice kaolin is most often used together with pectin in kaolin‑pectin suspensions for symptomatic treatment of acute diarrhea.atcddd.fhi+5
Pharmacology and mechanism
Kaolin (hydrated aluminum silicate, “white clay”) acts as a chemically inert adsorbent that binds bacteria, toxins, and water in the intestinal lumen and forms a protective coating on inflamed mucosa. This demulcent and adsorptive effect can modestly thicken stools and reduce irritation, although controlled studies in children show limited impact on stool frequency or total stool output.sciencedirect+5
Therapeutic indications
Within A07BC02, kaolin—usually as kaolin‑pectin liquid—is indicated as a short‑term symptomatic treatment for acute, non‑specific diarrhea and as a gastrointestinal protectant. These products are commonly available over the counter and are meant to be used alongside, not instead of, oral rehydration and etiological evaluation when indicated.drugs+2
Pharmacokinetics relevant to lactation
Kaolin has “zero bioavailability”: it is not absorbed from the maternal gastrointestinal tract and is eliminated unchanged in the feces. Because it does not enter the maternal circulation, kaolin is not expected to be transferred into human milk in any meaningful amount.ams.usda+1
Maternal safety profile
At usual oral doses for diarrhea, kaolin is generally well tolerated; constipation is the most common side effect, particularly with high or frequent dosing. Chronic or excessive intake (well beyond antidiarrheal doses) has been associated with intestinal obstruction, iron‑deficiency anemia, and possible heavy‑metal exposure in geophagia, but these scenarios differ markedly from short‑term medicinal use.webmd+2
Lactation safety assessment
Lactation‑specific references classify kaolin as compatible with breastfeeding and “not risky for breastfeeding or infant,” explicitly citing its lack of absorption and absence from breast milk. General reviews of gastrointestinal drugs in breastfeeding also regard short‑term use of non‑absorbed intestinal adsorbents as very low risk, especially compared with systemically active alternatives.pubmed.ncbi.nlm.nih+1
Potential effects on the breastfed infant
Because kaolin is not systemically absorbed by the mother, direct exposure of the infant via breast milk is expected to be negligible, and kaolin‑related toxicity or interference with infant nutrient absorption is not anticipated. Any risk to the infant is much more likely to arise from the underlying maternal illness (for example viral or bacterial gastroenteritis) or from co‑formulated active ingredients (such as opiates in older combination products), which require separate evaluation.pubmed.ncbi.nlm.nih+3
Practical use in breastfeeding women
For breastfeeding mothers with mild, self‑limited diarrhea, first‑line management remains oral rehydration and dietary adjustment, with contemporary guidance often favoring loperamide when an antidiarrheal drug is needed. Where kaolin‑containing products (commonly kaolin‑pectin) are used, they can generally be taken during breastfeeding without altering feeding schedules, provided dosing is short‑term and label directions are followed, while both mother and infant are monitored for persistence or worsening of symptoms.pubmed.ncbi.nlm.nih+5
Role among intestinal adsorbents
Compared with other intestinal adsorbents, kaolin combines an excellent toxico‑lactological profile with modest symptomatic benefit and has largely been supplanted by more effective agents in evidence‑based guidelines. Its local, non‑absorbed nature, however, makes it a very low‑risk option in breastfeeding when used appropriately and when alternatives are unavailable or unsuitable.pubmed.ncbi.nlm.nih+4



